Cooperation of imipramine blue and tyrosine kinase blockade demonstrates activity against chronic myeloid leukemia

The use of tyrosine kinase inhibitors (TKI), including nilotinib, has revolutionized the treatment of chronic myeloid leukemia (CML). However current unmet clinical needs include combating activation of additional survival signaling pathways in persistent leukemia stem cells after long-term TKI ther...

Descripción completa

Detalles Bibliográficos
Autores principales: Laidlaw, Kamilla M.E., Berhan, Samuel, Liu, Suhu, Silvestri, Giovannino, Holyoake, Tessa L., Frank, David A., Aggarwal, Bharat, Bonner, Michael Y., Perrotti, Danilo, Jørgensen, Heather G., Arbiser, Jack L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5239504/
https://www.ncbi.nlm.nih.gov/pubmed/27438151
http://dx.doi.org/10.18632/oncotarget.10541

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5239504/
https://www.ncbi.nlm.nih.gov/pubmed/27438151
http://dx.doi.org/10.18632/oncotarget.10541

Ejemplares similares